Table 1 Baseline characteristics
| Â | Urine albumin status | P-value | ||
|---|---|---|---|---|
Normoalbuminuria (n=452) | Microalbuminuria (n=155) | Macroalbuminuria (n=28) | ||
Age (years) | 50.48 ± 11.45 | 51.06 ± 11.31 | 53.57 ± 12.46 | 0.359 |
Male (%) | 197 (43.6%) | 70 (45.2%) | 12 (42.9%) | 0.937 |
BMI (kg/m2) | 23.54 ± 3.91 | 24.42 ± 3.93 | 25.88 ± 4.61 | 0.016 |
Systolic BP (mmHg) | 121.2 ± 16.45 | 122.49 ± 16.71 | 129.38 ± 21.48 | 0.048 |
Diastolic BP (mmHg) | 77.5 ± 9.19 | 79.58 ± 10.29 | 83.46 ± 13.27 | 0.002 |
History of Hypertension | 112 (24.8%) | 50 (32.3%) | 14 (50%) | 0.005 |
History of Type2 DM | 38 (8.4%) | 21 (13.5%) | 7 (25%) | 0.007 |
History of Dyslipidemia | 39 (8.6%) | 10 (6.5%) | 4 (14.3%) | 0.356 |
History of smoking (%) | 87 (19.2%) | 37 (23.9%) | 4 (14.3%) | 0.340 |
Serum creatinine (mg/dL) | 0.71 ± 0.19 | 0.68 ± 0.14 | 0.95 ± 0.48 | < 0.001 |
eGFR (ml/min/1.73m2) | 91.69 ± 18.85 | 93.28 ± 16.7 | 78.8 ± 26.21 | 0.026 |
Aspirin (use) | 28 (6.2%) | 21 (13.5%) | 4 (14.3%) | 0.009 |
ACEI/ARBs (use) | 45 (10%) | 31 (20%) | 6 (21.4%) | 0.002 |
Beta-Blockers (use) | 24 (5.3%) | 9 (5.8%) | 1 (3.6%) | 0.887 |
Amlodipine (use) | 29 (6.4%) | 15 (9.7%) | 3 (10.7%) | 0.323 |
Diuretics (use) | 46 (10.2%) | 16 (10.3%) | 5 (17.9%) | 0.436 |
Insulin (use) | 7 (1.5%) | 7 (4.5%) | 2 (7.1%) | 0.035 |
Metformin (use) | 30 (6.6%) | 18 (11.6%) | 4 (14.3%) | 0.072 |
Sulfonylurea (use) | 21 (4.6%) | 13 (8.4%) | 2 (7.1%) | 0.208 |
Simvastatin (use) | 45 (10%) | 15 (9.7%) | 3 (10.7%) | 0.985 |
Gemfibrozil (use) | 13 (2.9%) | 5 (3.2%) | 2 (7.1%) | 0.454 |